New non-oral drug delivery systems for Parkinson's disease treatment

Expert Opinion on Drug Delivery

Volumn 8, Issue 3, 2011, Pages 359-374

  Md, Shadab ^a   Haque, Shadabul ^a   Sahni, Jasjeet Kaur ^a   Baboota, Sanjula ^a   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

inhalational delivery; levodopa; non oral; Parkinson's disease; transdermal delivery

Indexed keywords

ADROGOLIDE; AMANTADINE; APOMORPHINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CARBOPOL 934; CATECHOL METHYLTRANSFERASE INHIBITOR; CHITOSAN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ETILEVODOPA; GANTREZ COPOLYMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; LENTIVIRUS VECTOR; LEVODOPA; LIPOSOME; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; NANOPARTICLE; NENAD; NEURTURIN; PARVOVIRUS VECTOR; PERGOLIDE; POLYMER; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VR 040; WITEPSOL H 15;

ADD ON THERAPY; BURNING SENSATION; CONTINUOUS INFUSION; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; GENE THERAPY; HUMAN; IONTOPHORESIS; MENTAL DISEASE; METERED DOSE INHALER; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; REVIEW; SKIN IRRITATION; SKIN NODULE; STOMATITIS; THROMBOSIS; ULCER;

ANTIPARKINSON AGENTS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; PARKINSON DISEASE;

EID: 79951867496     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.556616     Document Type: Review

References (145)

1. CNS Therapeutics Market Forecast Till 2015, Global Business Intelligence. London, United Kingdom; 2009
2. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64
3. Statistics by Country for Parkinson's disease, Wrong diagnosis. 2010. Available from: www.wrongdiagnosis.com/p/ parkinsons-disease/books.htm [Last accessed 18 August 2010]
4. Therapeutic focus - Parkinson's disease in need of fresh impetus, Evaluate Pharma; 2009. Available from: www.epvantage.com/Universal/ View.aspx?type=Story&id. [Last accessed 8 August 2010]
5. Fahn S. Levodopa in the treatment of Parkinson's disease. J Neural Transm 2006;71(Suppl):1-15
6. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;13(62):47-55
7. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999;14(5):725-30 (Pubitemid 29509613)
8. Weiner WJ. The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord 1999;14(5):716-24 (Pubitemid 29509612)
9. Wooten GF. Agonists vs levodopa in PD: the thrilla of whitha. Neurology 2003;60(3):360-2 (Pubitemid 36188226)
10. Stefano AD, Sozio P, Lannitelli A, Cerasa LS. New drug delivery strategies for improved parkinson disease therapy. Expert Opin Drug Deliv 2009;6(4):389-404
11. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-55
12. Hely MA, Morris J, Reid WGJ, et al. Sydney multicenter study of Parkinson's disease: non-motor problems dominate at 15 years. Mov Disord 2005;20:190-9 (Pubitemid 40361122)
13. Adams JD, Odunze IN. Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 1991;10:161-9 (Pubitemid 121003223)
14. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003;16:S3-7 (Pubitemid 38328107)
15. Yuan H, Sarre S, Ebinger G, Michotte Y. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Res 2004;1026:95-107 (Pubitemid 39336420)
16. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006;13:1170-85 (Pubitemid 44581464)
17. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95 (Pubitemid 44044780)
18. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56:S1-88
19. Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet 2002;41:171-86 (Pubitemid 34415836)
20. Pardridge WM. Recent advances in blood brain-barrier transport. Annu Rev Pharmacol Toxicol 1988;28:25-39
21. Wang Y, Liu ZZ, Chen SZ. Synthesis of a Dopamimetic Thionated Dipeptide Prodrug of L-DOPA. Chin Chem Lett 2005;16(6):713-15 (Pubitemid 43872285)
22. Bodor N, Buchwald P, Drug targeting via retrometabolic approaches. Pharmacol Ther 1997;76:1-27 (Pubitemid 28078557)
23. Bergley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996;48:136-46
24. Pilar C, Bruno G, Helene C, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001;18(8):1157-66
25. Lambert DM. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 2000;11:S15-27
26. Wu J, Yoon SH, Wu WM, Bodor N. Synthesis and biological evaluation of a brain targeted chemical delivery system of [Nva2]-TRH. J Pharm Pharmacol 2002;54:945-50 (Pubitemid 34763839)
27. Kreuter J. Nanoparticlate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81 (Pubitemid 32209233)
28. Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem 2002;2:241-9 (Pubitemid 36267728)
29. Doran SE, Ren XD, Betz AL, et al. Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery 1995;36:965-70
30. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 2010;99:1-20
31. Oertel W, Ross JS, Eggert K, Adler G. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69:4-9
32. Seeberger LC, Hauser RA. Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacol 2007;53:791-800 (Pubitemid 350018828)
33. Poewe W, Luessi F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 2005;65:S11-14 (Pubitemid 41022401)
34. Zareba G. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. Drugs Today (Barc) 2006;42(1):21-8
35. Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy 2009;29(12):1452-67
36. Neupro European summary of product characteristics. Available from: http:// www.emea.europa.eu/humandocs/PDFs/ EPAR/neupro/emea-combined-h626en. pdf [Last accessed 15 March 2010]
37. Chaudhuri KR. Crystallisation within transdermal rotigotine patch: is there cause for concern? Expert Opin Drug Deliv 2008;5(11):1169-71
38. General information on Lisuride TDS and Lisuride sc. Available from: www. axxonis.com/projects-e.html [Last accessed 22 October 2010]
39. Woitalla D, Muller T, Benz S, Horowski R. Transdermal lisuride delivery in the treatment of Parkinson disease. J Neural Transm 2004;68:89-95 (Pubitemid 39215441)
40. Peira E, Scolari P, Gasco MR. Transdermal permeation of apomorphine through hairless mouse skin from microemulsions. Int J Pharm 2001;226(1-2):47-51 (Pubitemid 32800781)
41. Addressing unmet need in management of parkinson disease. Drug Deliv Technol 2007;60-63. Available from: www.alteatherapeutics.com/.../ OnDrugDelivery-Final.pdf [Last accessed 15 October 2010]
42. Degim IT, Acarturk F, Erdogan D, Lortlar ND. Transdermal administration of bromocriptine. Bio Pharm Bull 2003;26(4):501-5 (Pubitemid 39663596)
43. Chen TF, Chiang CM. Transdermal administration of ropinirole and analogs thereof. US5807570; 1998
44. Yum Su II, Nelson MK, Campbell PS. Formulations for transdermal delivery of pergolide. WO040139; 1996
45. Forlando P, Scasso A, Stefeno F. Transdermal drug delivery system for liquid active ingredient. US0087678A1; 2010
46. Kushnir M, Eliahu H. Apparatus for the transdermal treatment of parkinsons disease. US6746688; 2004
47. Dipierro G, Steven A. Biosynchronous transdermal drug delivery for parkinsons disease. US0220092; 2008
48. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004;56(4):619-58 (Pubitemid 38326937)
49. Li LG, Bouwastra AJ, Wolff M, Nugroho KA. Iontophoretic delivery of rotigotine for the treatment of parkinsons disease. US007632859B2; 2009
50. Laar V, Geest TV, Gubbens-Stibbe JM, et al. Iontophoretic delivery of Apomorphine II: an in vivo study in patients with Parkinson's disease. Pharm Res 1997;14(12):1804-10 (Pubitemid 28062929)
51. Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technol Today 1999;2:49-59 (Pubitemid 29130313)
52. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18 (Pubitemid 30410839)
53. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56:3-17 (Pubitemid 38195323)
54. Van Laar T, Jansen ENH, Essink AWG, Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992;49:482-4
55. Sam E, Jeanjean AP, Maloteaux JM, Verbeke N. Apomorphine pharmacokinetics after intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995;20:27-33
56. Corboy DL, Wagner ML, Sage, JI. Apomorphine for motor fluctuation and freezing in Parkinson's disease. Ann Pharmacother 1995;29:282-8
57. Ugwoke MI, Sam E, Mooter GVD, et al. Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits. Int J Pharm 1999;181:125-38 (Pubitemid 29199894)
58. Information on apomorphine nasal powder. Britannia products in developments. Available from: www. britannia-pharm.co.uk/partnerships. shtml#Apo-nasal%20PD [Last accessed 10 October 2010]
59. Brime B, Ballesteros MP, Frutos P. Preparation and in vitro characterization of gelatin microspheres containing levodopa for nasal administration. J Microencapsul 2000;17(6):777-84
60. Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17(8):978-84
61. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994;7:49-75 (Pubitemid 24277024)
62. Jackson B, Bennett DJ, Bartus RT, Emerich DF. Pulmonary delivery for levodopa. Application: US8659 2003079992; 2003
63. Bartus RT, Emerich DF. Pulmonary delivery in treating disorders of the central nervous system. Application: 006514482B1, 2003
64. Bartus RT, Emerich DR. Pulmonary delivery in treating disorders of the central nervous system. Application: WOUS293112002024158; 2001
65. Bartus RT, Emerich D, Snodgrass-Belt P, et al. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:828-35 (Pubitemid 38988931)
66. Zheng Y, Marsh KC, Bertz RJ, et al. Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. Int J Pharm 1999;191:131-40 (Pubitemid 29516477)
67. De-Vries ME, Bodde HE, Verhoef JC, Junginger HE. Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst 1991;8:271-303
68. Montastruc JL, Rascol O Senard JM, Gualano V. Sublingual Apomorphine in Parkinson's disease: a Clinical and Pharmacokinetic Study. Clinic Neuro Pharm 1991;14(5):373-463
69. Amarin acquires Parkinson's disease drug candidate oral formulation of apomorphine to treat 'off ' episode. The free library. Available from: www.amarincorp.com [Last accessed 23 October 2010]
70. Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110 11):1273-8
71. Zelapar website. Available from: www.zelapar.com [Last accessed 20 October 2010]
72. H. Seager. Drug delivery products and the Zydis Fast-Dissolving Dosage form. J Pharm Pharmacol 1998;50(4):375-82 (Pubitemid 28197414)
73. Eisler T, Eng N, Plotkin C, Calne DB. Absorption of levodopa after rectal administration. Neurology 1981;31(2):215-17 (Pubitemid 11137609)
74. Cooper SD, Ismail HA, Frank C. Case report: successful use of rectally administered levodopa-carbidopa. Can Fam Phys 2001;47:112-13 (Pubitemid 32182629)
75. Laar TV, Jansen ENH, Neef C, et al. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 2004;10(4):433-9
76. Langer R. Polymer implants for drug delivery in the brain. J Contr Rel 1991;16:53-60
77. Kroll RA, Pagel MA, Maldoon LL, et al. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 1996;38:746-54 (Pubitemid 26089861)
78. Tamargo RJ. Brem H. Drug delivery to the central nervous system: a review. Neurosurg 1992;2:259-79 (Pubitemid 23016857)
79. Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in gliomabearing rats by intracarotid infusion of the bradykinin analog, RMP-7. Neurosurgery 1996;39:125-33
80. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res 1995;680:196-206
81. Menei P, Benoit JP, Boisdron-Celle M, et al. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994;34:1058-64 (Pubitemid 24174248)
82. Mittal S, Cohen A, Maysinger D. In vitro effects of brain derived neurotrophic factor released from microspheres. Neuro Report 1994;5:2577-82
83. Benoit JP, Faisant N, Venier-Julienne MC, Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J Contr Rel 2000;65:285-96 (Pubitemid 30122933)
84. McRae A, Dahlstrom A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OHDA induced parkinsonism. Neurochem Int 1994;25:27-33 (Pubitemid 24229662)
85. McRae A, Ling EA, Hjorth S, et al. Catecholamine-containing biodegradable microspheres implants as a novel approach in the treatment of CNS neurodegenerative disease. A review of experimental studies in DA-lesioned rats. Mol Neurobiol 1994;9:191-205
86. Arica B, Kas HS, Moghdam A, et al. Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. J Contr Rel 2005;102:689-97 (Pubitemid 40170211)
87. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived nerotrophic factor in Parkinson disease. Nat Med 2003;9:589-95 (Pubitemid 36597106)
88. Patel NK, Bunnage M, Plaha P, et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005;57:298-302 (Pubitemid 40179870)
89. Slevin JT, Gerhardt GA, Smith, CDet al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell linederived neurotrophic factor. J Neurosurg 2005;102:216-22 (Pubitemid 43194069)
90. Amgen Incorporated: Amgen's phase 2 study of GDNF for advanced Parkinson's disease fails to meet primary endpoint; six months of treatment showed biological effect but no clinical improvement, 2004. Available form: http://amgen.com/news/viewPR.jsp? id=585632 [Last accessed 12 October 2010]
91. Pollack A. Patients in test won't get drug, Amgen decides. NY Times, 2005 February 12, C1:C2
92. Garbayo E, Ansorena E, Lanciego JL, et al. Sustained release of bioactive glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur J Pham Biophar 2008;69(3):844-51
93. Garbayo E, Montero-Menei CN, Ansorena E, et al. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease. J Contr Rel 2009;135:119-26
94. Jenkins OF, Jackson DM. Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats. Neuropharmacology 1986;25(11):1243-9 (Pubitemid 17185883)
95. Donovan S, Beach C. Parkinsons disease treatment. US006620415B2; 2003
96. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Quart J Med 1980;49:283-93 (Pubitemid 11240660)
97. Hardie RJ, Malcolm SI, Lees AJ, et al. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J clin Pharmac 1986;22:429-36 (Pubitemid 16003190)
98. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;320(8295):412-15 (Pubitemid 12039838)
99. Juncos JL, Mouradian MM, Fabbrini G, et al. LD methyl ester treatment of Parkinson's disease. Neurology 1987;37(7):1242-50
100. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124(2):331-40 (Pubitemid 32142405)
101. Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20(2):262-5 (Pubitemid 16044214)
102. Kurlan R, Nutt JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 1988;23(6):589-95
103. Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97(3):175-83 (Pubitemid 28254914)
104. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13:13-17
105. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert opin Pharmacother 2007;8(5):657-64 (Pubitemid 46547018)
106. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006;6(10):1403-11 (Pubitemid 44696265)
107. Available from: www.duodopa.com [Last accessed 20 October 2010]
108. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005:25;64(2):216-23
109. Antonini A, Mancini F, Canesi M, Zangaglia R. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008;5(3-4):244-6 (Pubitemid 351347862)
110. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson'sdisease: long-term follow-up study of 64 patients. Mov Disord 2002;17(6):1235-41 (Pubitemid 36041337)
111. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21(11):687-709 (Pubitemid 39273964)
112. Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Clin Ther 2005;27(11):1710-24 (Pubitemid 41815224)
113. Stocchi F, Ruggieri S, Carta A, et al. Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease. Mov Disord 1992;7:249-56
114. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain 1991;114:601-17
115. Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125(9):2058-66
116. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993;60:653-5
117. General information on Lisuride TDS and Lisuride sc. Available from: www. axxonis.com/projects-e.html [Last accessed 20 October 2010]
118. Kaplitt MG. Another player in gene therapy for Parkinson disease. Nat Rev Neurol 2010;6:7-8
119. Jarraya B. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science Trans Med 2009;1:1-10
120. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-105 (Pubitemid 46935946)
121. Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-8
122. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73:1662-9
123. Muramatsu S, Fuzimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002;13:345-54 (Pubitemid 34251500)
124. Ralph GS, Binley K, Wong LF, Azzouz M. Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors. Clin Sci 2006;110:37-46 (Pubitemid 43065055)
125. Burton EA, Glorioso JC, Fink DJ. Gene therapy progress and prospects: Parkinson's disease. Gene Ther 2003;10:1721-7 (Pubitemid 37121043)
126. During MJ, Freese A, Deutch AY, et al. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp Neurol 1992;115:193-9
127. Pichandy M, Manisha-Mishra M, Kanaiyan S, et al. Formulation and psychopharmacological evaluation of surfactant modified liposome for parkinsonism disease. Asian J Pharm Clinic Res 2010;3(1):46-54
128. Ochoteco E, Murillo N, Rodriguez J, et al. In: Dickey EC, editor, Encyclopaedia of sensors. Intrinsically conducting polymers based electrochemical, vol. X. American Scientific Publishers, USA; 2006. p. 1-19
129. Lavan A, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;10:1184-91 (Pubitemid 37186175)
130. Esposito E, Fantin M, Marti M, et al. Solid lipid nanoparticles as delivery systems for Bromocriptine. Pharm Res 2008;25:1521-30
131. Pillay S, Pillay V, Choonara Y, et al. Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Pharm Nanotech 2009;382:277-90
132. Linazasoro G. Neuroprotection and neurorescue in Parkinson's disease: love story or mission impossible? Exp Rev Neurother 2002;2:403-16 (Pubitemid 34627346)
133. Dugan L, Lovett G, Quick L, et al. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 2001;7:243-6 (Pubitemid 32372506)
134. Bharali J, Klejbor I, Stachowiak K, et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA 2005;102:11539-44 (Pubitemid 41153855)
135. Bai S, Thomas C, Rawat A, Ahsan F. Recent progress in dendrimer-based nanocarriers. Crit Rev Ther Drug Carrier Syst 2006;23:437-95 (Pubitemid 46568172)
136. Luo D, Li Y. Dendrimer-like modular delivery vector. US20100136614; 2010
137. Lee C, MacKay J, Frechet J, Szoka F. Designing dendrimers for biological applications. Nat Biotechnol 2005;23:1517-26 (Pubitemid 41752929)
138. Gao Y, Gao G, He Y, et al. Recent advances of dendrimers in delivery of genes and drugs. Mini Rev Med Chem 2008;8:889-900
139. Pereira AC, Green L, Nandi D, Aziz Z. Deep brain stimulation: indications and evidence. Expert Rev Med Device 2007;4(5):591-603 (Pubitemid 47499967)
140. Toselli R, Thomas M, Fisher M. Endoscopic delivery of red/nir light to substantia nigra to treat Parkinson's disease. US0222067A1; 2009
141. Xu J, Zhong N. Use of androgens for the treatment of parkinsons disease. US0325911; 2009
142. Aderis Pharmaceuticals website. Available from: www.aderis.com/ products/rotigotine.htm [Last accessed 12 January 2010]
143. Vectura product pipeline and product profiles. Available from: www.vectura. com/vec/products/pipeline/profiles [Last accessed 14 January 2010]
144. Apokyn website. Available from: www.apokyn.com/ [Last accessed 13 January 2010]
145. Apo-go website. Available from: www.apo-go.co.uk/index.htm. [Last accessed 13 January 2010]